190 related articles for article (PubMed ID: 24608161)
1. Quantitative serial MRI of the treated fibroid uterus.
Munro KI; Thrippleton MJ; Williams AR; McKillop G; Walker J; Horne AW; Newby DE; Anderson RA; Semple SI; Marshall I; Lewis SC; Millar RP; Bastin ME; Critchley HO
PLoS One; 2014; 9(3):e89809. PubMed ID: 24608161
[TBL] [Abstract][Full Text] [Related]
2. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
3. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
[TBL] [Abstract][Full Text] [Related]
4. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
5. Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging.
Williams IA; Shaw RW
Eur J Obstet Gynecol Reprod Biol; 1990; 34(1-2):111-7. PubMed ID: 2137421
[TBL] [Abstract][Full Text] [Related]
6. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
Felberbaum RE; Germer U; Ludwig M; Riethmüller-Winzen H; Heise S; Buttge I; Bauer O; Reissmann T; Engel J; Diedrich K
Hum Reprod; 1998 Jun; 13(6):1660-8. PubMed ID: 9688409
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
8. Potential benefit of GnRH-agonist treatment before uterine artery embolization for large fibroids: MRI prediction of fibroid volume reduction.
Lee WJ; Kim MD; Han K; Won YR; Alqahtani A; Moon S; An H
Acta Radiol; 2022 Oct; 63(10):1425-1432. PubMed ID: 34565214
[TBL] [Abstract][Full Text] [Related]
9. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
10. Mid-term clinical efficacy of a volumetric magnetic resonance-guided high-intensity focused ultrasound technique for treatment of symptomatic uterine fibroids.
Ikink ME; Voogt MJ; Verkooijen HM; Lohle PN; Schweitzer KJ; Franx A; Mali WP; Bartels LW; van den Bosch MA
Eur Radiol; 2013 Nov; 23(11):3054-61. PubMed ID: 23793518
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
12. Herbal preparations for uterine fibroids.
Liu JP; Yang H; Xia Y; Cardini F
Cochrane Database Syst Rev; 2013 Apr; (4):CD005292. PubMed ID: 23633329
[TBL] [Abstract][Full Text] [Related]
13. [Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix].
Felberbaum RE; Ludwig M; Diedrich K
Contracept Fertil Sex; 1999 Oct; 27(10):701-9. PubMed ID: 10605180
[TBL] [Abstract][Full Text] [Related]
14. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function.
Perrone AM; Pozzati F; Di Marcoberardino B; Rossi M; Procaccini M; Pellegrini A; Santini D; De Iaco P
J Obstet Gynaecol Res; 2014 Jan; 40(1):117-24. PubMed ID: 24033631
[TBL] [Abstract][Full Text] [Related]
15. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Pandian MR; Heffner LJ
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
[TBL] [Abstract][Full Text] [Related]
16. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
[TBL] [Abstract][Full Text] [Related]
17. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
18. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids.
Lumsden MA; West CP; Thomas E; Coutts J; Hillier H; Thomas N; Baird DT
Br J Obstet Gynaecol; 1994 May; 101(5):438-42. PubMed ID: 8018618
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of magnetic resonance imaging-guided high intensity focused ultrasound therapy for ablating uterine fibroids in patients with bowel lies anterior to uterus.
Zhang L; Chen WZ; Liu YJ; Hu X; Zhou K; Chen L; Peng S; Zhu H; Zou HL; Bai J; Wang ZB
Eur J Radiol; 2010 Feb; 73(2):396-403. PubMed ID: 19108974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
